477 related articles for article (PubMed ID: 28133913)
1. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW
Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
3. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line.
Ren J; Chen Y; Song H; Chen L; Wang R
J Cell Biochem; 2013 Jun; 114(6):1395-403. PubMed ID: 23255418
[TBL] [Abstract][Full Text] [Related]
5. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Orellana-Serradell O; Herrera D; Castellón EA; Contreras HR
Asian J Androl; 2019; 21(5):460-467. PubMed ID: 30880686
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 co-expression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer.
Chu PY; Hu FW; Yu CC; Tsai LL; Yu CH; Wu BC; Chen YW; Huang PI; Lo WL
Oral Oncol; 2013 Jan; 49(1):34-41. PubMed ID: 22892238
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of ZEB1 reverses cancer stem cell properties in prostate cancer cells.
Pérez G; López-Moncada F; Indo S; Torres MJ; Castellón EA; Contreras HR
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760173
[TBL] [Abstract][Full Text] [Related]
8. Role of ZEB Family Members in Proliferation, Metastasis, and Chemoresistance of Prostate Cancer Cells: Revealing Signaling Networks.
Soleymani L; Zarrabi A; Hashemi F; Hashemi F; Zabolian A; Banihashemi SM; Moghadam SS; Hushmandi K; Samarghandian S; Ashrafizadeh M; Khan H
Curr Cancer Drug Targets; 2021; 21(9):749-767. PubMed ID: 34077345
[TBL] [Abstract][Full Text] [Related]
9. MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.
Guo F; Cogdell D; Hu L; Yang D; Sood AK; Xue F; Zhang W
Oncol Rep; 2014 May; 31(5):2021-8. PubMed ID: 24677166
[TBL] [Abstract][Full Text] [Related]
10. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.
Korpal M; Lee ES; Hu G; Kang Y
J Biol Chem; 2008 May; 283(22):14910-4. PubMed ID: 18411277
[TBL] [Abstract][Full Text] [Related]
11. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.
Kong D; Li Y; Wang Z; Banerjee S; Ahmad A; Kim HR; Sarkar FH
Stem Cells; 2009 Aug; 27(8):1712-21. PubMed ID: 19544444
[TBL] [Abstract][Full Text] [Related]
12. Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT.
Zhao L; Li X; Song N; Li A; Hou K; Qu X; Che X; Liu Y
Cell Biol Int; 2018 Mar; 42(3):294-302. PubMed ID: 29052277
[TBL] [Abstract][Full Text] [Related]
13. ZEB1-responsive genes in non-small cell lung cancer.
Gemmill RM; Roche J; Potiron VA; Nasarre P; Mitas M; Coldren CD; Helfrich BA; Garrett-Mayer E; Bunn PA; Drabkin HA
Cancer Lett; 2011 Jan; 300(1):66-78. PubMed ID: 20980099
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
15. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.
Putzke AP; Ventura AP; Bailey AM; Akture C; Opoku-Ansah J; Celiktaş M; Hwang MS; Darling DS; Coleman IM; Nelson PS; Nguyen HM; Corey E; Tewari M; Morrissey C; Vessella RL; Knudsen BS
Am J Pathol; 2011 Jul; 179(1):400-10. PubMed ID: 21703419
[TBL] [Abstract][Full Text] [Related]
16. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G
Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752
[TBL] [Abstract][Full Text] [Related]
17. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.
Leshem O; Madar S; Kogan-Sakin I; Kamer I; Goldstein I; Brosh R; Cohen Y; Jacob-Hirsch J; Ehrlich M; Ben-Sasson S; Goldfinger N; Loewenthal R; Gazit E; Rotter V; Berger R
PLoS One; 2011; 6(7):e21650. PubMed ID: 21747944
[TBL] [Abstract][Full Text] [Related]
18. Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1
Qian J; Shen S; Chen W; Chen N
Biomed Res Int; 2018; 2018():4174232. PubMed ID: 29568752
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.
Graham TR; Zhau HE; Odero-Marah VA; Osunkoya AO; Kimbro KS; Tighiouart M; Liu T; Simons JW; O'Regan RM
Cancer Res; 2008 Apr; 68(7):2479-88. PubMed ID: 18381457
[TBL] [Abstract][Full Text] [Related]
20. Ets1 and ESE1 reciprocally regulate expression of ZEB1/ZEB2, dependent on ERK1/2 activity, in breast cancer cells.
Sinh ND; Endo K; Miyazawa K; Saitoh M
Cancer Sci; 2017 May; 108(5):952-960. PubMed ID: 28247944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
